Human health

Overview

Right now, our human health project pipeline is focused on tackling two of the largest health challenges of our time – finding safe and effective treatments for multidrug resistant Gram negative and Gram positive bacterial infections and thereby countering the spread of antimicrobial resistance indirectly. Lowering the burden of living with persistent infections and the financial cost of treating these infections goes hand-in-hand with reducing the impact and ongoing spread of antimicrobial resistance more broadly. Neem is using a novel approach to target the management of bacterial virulence factors as one of the drivers of these costly and hard-hitting healthcare challenges.

Respiratory Infections in Cystic Fibrosis

NX-AS-401 is a potential new treatment for chronic lung infections in patients with cystic fibrosis. It is designed to help eradicate the Pseudomonas aeruginosa bacterial infections that are the key cause of death for cystic fibrosis patients.

NX-AS-401 has a novel mechanism of action. As a quorum sensing inhibitor it disrupts communication between bacteria. This minimies both their ability to directly damage the surrounding lung tissue and to form the biofilm that is crucial in protecting them from current anti-Pseudomonal antibiotics.

Infection Control in Wounds

Hard-to-heal wounds are those that fail to heal within 12 weeks. These wounds are frequently complex and management can therefore be lengthy and costly both for individuals and societies.

Unfortunately, current prevalence figures for infected hard-to-heal wounds are set to rise in coming years as more of us live longer and the effects of chronic lifestyle-related diseases such as diabetes and obesity take hold.

Control of infection in these wounds is key if the right conditions are to be created for them to heal. NX-AS-911 is a potential new treatment for this challenging situation. It disrupts communication between the biofilm forming Staphylococcus aureus and Pseudomonas aeruginosa bacteria that are frequently found in these wounds. In turn, this prevents these bacteria from activating their genetically programmed virulence factors that give rise to damage to the tissue in which the bacteria are located and from forming the biofilm that is crucial in protecting themselves both from current antibiotics that may be used and from the body's own immune system.

 

Human health

Overview

Right now, our human health project pipeline is focused on tackling two of the largest health challenges of our time – finding safe and effective treatments for multidrug resistant Gram negative and Gram positive bacterial infections and thereby countering the spread of antimicrobial resistance indirectly. Lowering the burden of living with persistent infections and the financial cost of treating these infections goes hand-in-hand with reducing the impact and ongoing spread of antimicrobial resistance more broadly. Neem is using a novel approach to target the management of bacterial virulence factors as one of the drivers of these costly and hard-hitting healthcare challenges.

Respiratory Infections in Cystic Fibrosis

NX-AS-401 is a potential new treatment for chronic lung infections in patients with cystic fibrosis. It is designed to help eradicate the Pseudomonas aeruginosa bacterial infections that are the key cause of death for cystic fibrosis patients.

NX-AS-401 has a novel mechanism of action. As a quorum sensing inhibitor it disrupts communication between bacteria. This minimies both their ability to directly damage the surrounding lung tissue and to form the biofilm that is crucial in protecting them from current anti-Pseudomonal antibiotics.

Infection Control in Wounds

Hard-to-heal wounds are those that fail to heal within 12 weeks. These wounds are frequently complex and management can therefore be lengthy and costly both for individuals and societies.

Unfortunately, current prevalence figures for infected hard-to-heal wounds are set to rise in coming years as more of us live longer and the effects of chronic lifestyle-related diseases such as diabetes and obesity take hold.

Control of infection in these wounds is key if the right conditions are to be created for them to heal. NX-AS-911 is a potential new treatment for this challenging situation. It disrupts communication between the biofilm forming Staphylococcus aureus and Pseudomonas aeruginosa bacteria that are frequently found in these wounds. In turn, this prevents these bacteria from activating their genetically programmed virulence factors that give rise to damage to the tissue in which the bacteria are located and from forming the biofilm that is crucial in protecting themselves both from current antibiotics that may be used and from the body's own immune system.